Nuveen LLC purchased a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 92,957 shares of the company's stock, valued at approximately $1,028,000. Nuveen LLC owned approximately 0.20% of Urogen Pharma at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of URGN. Lazard Asset Management LLC bought a new stake in shares of Urogen Pharma in the 4th quarter valued at about $67,000. Janus Henderson Group PLC acquired a new position in Urogen Pharma during the fourth quarter worth approximately $149,000. ProShare Advisors LLC bought a new stake in Urogen Pharma in the fourth quarter valued at approximately $137,000. Rhumbline Advisers lifted its position in shares of Urogen Pharma by 4.3% in the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock valued at $591,000 after buying an additional 2,196 shares during the last quarter. Finally, Vestal Point Capital LP boosted its stake in shares of Urogen Pharma by 307.5% during the 4th quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company's stock worth $17,360,000 after acquiring an additional 1,230,000 shares during the period. Institutional investors own 91.29% of the company's stock.
Analyst Ratings Changes
A number of research firms recently weighed in on URGN. D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. HC Wainwright decreased their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Guggenheim restated a "buy" rating and set a $30.00 target price (up previously from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Oppenheimer set a $31.00 target price on shares of Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Finally, Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Urogen Pharma has a consensus rating of "Buy" and an average price target of $32.00.
Check Out Our Latest Stock Analysis on Urogen Pharma
Urogen Pharma Stock Performance
NASDAQ:URGN traded down $0.57 during mid-day trading on Thursday, reaching $18.80. 1,891,134 shares of the company's stock were exchanged, compared to its average volume of 1,530,611. Urogen Pharma has a one year low of $3.42 and a one year high of $21.01. The business's fifty day simple moving average is $17.32 and its two-hundred day simple moving average is $12.41. The firm has a market capitalization of $869.69 million, a PE ratio of -5.66 and a beta of 1.10.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). The business had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.
Insiders Place Their Bets
In related news, General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $143,971.08. Following the transaction, the general counsel owned 41,492 shares in the company, valued at approximately $794,156.88. This trade represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Schoenberg sold 10,000 shares of the company's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $17.69, for a total transaction of $176,900.00. Following the sale, the insider directly owned 148,229 shares of the company's stock, valued at $2,622,171.01. This represents a 6.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,833 shares of company stock worth $457,467 in the last 90 days. 4.70% of the stock is owned by company insiders.
Urogen Pharma Company Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
